Bristol-Myers Squibb
Market Cap
US$87.0b
Last Updated
2019/10/21 23:33 UTC
Data Sources
Company Financials +
Executive Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake
Fundamentals
Undervalued with high growth potential and pays a dividend.
Similar Companies
Share Price & News
How has Bristol-Myers Squibb's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
3.2%
BMY
0.06%
US Pharmaceuticals
0.5%
US Market
1 Year Return
4.6%
BMY
-7.8%
US Pharmaceuticals
6.8%
US Market
Return vs Industry: BMY exceeded the US Pharmaceuticals industry which returned -7.8% over the past year.
Return vs Market: BMY underperformed the US Market which returned 6.8% over the past year.
Shareholder returns
| BMY | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.2% | 0.06% | 0.5% |
| 30 Day | 5.2% | -1.7% | -0.8% |
| 90 Day | 23.6% | -1.3% | -0.9% |
| 1 Year | 8.2%4.6% | -5.5%-7.8% | 9.2%6.8% |
| 3 Year | 17.9%8.1% | 18.4%10.1% | 45.6%36.2% |
| 5 Year | 13.7%-0.6% | 22.2%9.3% | 63.2%45.4% |
Price Volatility Vs. Market
How volatile is Bristol-Myers Squibb's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Does Bristol-Myers Squibb Company's (NYSE:BMY) CEO Salary Compare Well With Others?3 weeks ago | Simply Wall St
Is It Smart To Buy Bristol-Myers Squibb Company (NYSE:BMY) Before It Goes Ex-Dividend?1 month ago | Simply Wall St
Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Rather SparinglyValuation
Is Bristol-Myers Squibb undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BMY ($53.2) is trading below our estimate of fair value ($250.41)
Significantly Below Fair Value: BMY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BMY is good value based on its PE Ratio (14x) compared to the Pharmaceuticals industry average (16x).
PE vs Market: BMY is good value based on its PE Ratio (14x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: BMY is good value based on its PEG Ratio (0.3x)
Price to Book Ratio
PB vs Industry: BMY is overvalued based on its PB Ratio (5.4x) compared to the US Pharmaceuticals industry average (2.9x).
Next Steps
Future Growth
How is Bristol-Myers Squibb forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
47.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BMY's forecast earnings growth (47% per year) is above the savings rate (2.7%).
Earnings vs Market: BMY's earnings (47% per year) are forecast to grow faster than the US market (14.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BMY's revenue (15.7% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: BMY's revenue (15.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BMY's Return on Equity is forecast to be high in 3 years time (26.3%)
Next Steps
Past Performance
How has Bristol-Myers Squibb performed over the past 5 years?
13.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: BMY's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: BMY's earnings growth over the past year (1549.7%) exceeds its 5-year average (13% per year).
Earnings vs Industry: BMY earnings growth over the past year (1549.7%) exceeded the Pharmaceuticals industry 24.3%.
Return on Equity
High ROE: Whilst BMY's Return on Equity (38.54%) is high, this metric is skewed due to their high level of debt.
Return on Assets
ROA vs Industry: BMY has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: BMY's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Bristol-Myers Squibb's financial position?
Financial Position Analysis
Short Term Liabilities: BMY's short term assets ($37.7B) exceeds its short term liabilities ($9.7B)
Long Term Liabilities: BMY's short term assets (37.7B) exceeds its long term liabilities (29.3B)
Debt to Equity History and Analysis
Debt Level: BMY's debt to equity ratio (156.1%) is considered high
Reducing Debt: BMY's debt to equity ratio has increased from 50.3% to 156.1% over the past 5 years.
Debt Coverage: BMY's debt is well covered by operating cash flow (28.5%).
Interest Coverage: BMY earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: BMY has a low level of unsold assets or inventory.
Debt Coverage by Assets: BMY's debt is covered by short term assets (assets are 1.495590x debt).
Next Steps
Dividend
What is Bristol-Myers Squibb's current dividend yield, its reliability and sustainability?
3.08%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: BMY's dividend (3.08%) is higher than the bottom 25% of dividend payers in the US market (1.45%).
High Dividend: BMY's dividend (3.08%) is low compared to the top 25% of dividend payers in the US market (3.73%).
Stable Dividend: BMY's dividends per share have been stable in the past 10 years.
Growing Dividend: BMY's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (42.9%), BMY's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BMY's dividends in 3 years are forecast to be well covered by earnings (23.1% payout ratio).
Next Steps
Management
What is the CEO of Bristol-Myers Squibb's salary, the management and board of directors tenure and is there insider trading?
4.2yrs
Average management tenure
CEO
Giovanni Caforio (54yo)
4.4yrs
Tenure
US$19,379,755
Compensation
Dr. Giovanni Caforio, M.D. serves as the Chief Executive Officer at Bristol-Myers Squibb Belgium NV/SA. Dr. Caforio has been the Chief Executive Officer of Bristol-Myers Squibb Farmacêutica Portuguesa, SA ...
CEO Compensation Analysis
Compensation vs. Market: Giovanni's total compensation ($USD19.38M) is about average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Giovanni's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.2yrs
Average Tenure
57yo
Average Age
Experienced Management: BMY's management team is considered experienced (4.2 years average tenure).
Board Age and Tenure
3.2yrs
Average Tenure
62yo
Average Age
Experienced Board: BMY's board of directors are considered experienced (3.2 years average tenure).
Insider Trading
Insider Buying: BMY insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 11,000 |
| Max Price | US$44.72 |
| Entity | Individual |
| Shares | 5,000 |
| Max Price | US$47.29 |
| Entity | Individual |
| Shares | 3,065 |
| Max Price | US$47.56 |
| Entity | Company |
| Shares | 1,076,321 |
| Max Price | US$51.71 |
| Entity | Company |
| Shares | 9,877,502 |
| Max Price | US$52.42 |
Ownership Breakdown
Management Team
Sandy Leung (58yo)
Executive VP & General Counsel
- Tenure: 12.7yrs
- Compensation: US$6.24m
John Elicker (59yo)
Senior Vice President of Corporate Affairs & Investor Relations
- Tenure: 2.8yrs
Giovanni Caforio (54yo)
Chairman of the Board & CEO
- Tenure: 4.4yrs
- Compensation: US$19.38m
Charlie Bancroft (59yo)
Executive VP of Global Business Operations & CFO
- Tenure: 9.5yrs
- Compensation: US$7.89m
Paul von Autenried (57yo)
Senior VP & Chief Information Officer
- Tenure: 7.8yrs
Lou Schmukler (63yo)
Senior VP and President of Global Product Development & Supply
- Tenure: 2.8yrs
- Compensation: US$4.13m
Ann Powell (53yo)
Senior VP & Chief Human Resources Officer
- Tenure: 3.3yrs
Jitendra Tyagi
Head of US Drug Makers - India
- Tenure: 5.3yrs
Paul Biondi (49yo)
Head of Strategy & Business Development and Senior VP
- Tenure: 4yrs
Adam Dubow (52yo)
Senior VP & Chief Compliance and Ethics Officer
- Tenure: 1.8yrs
Board Members
Jerry Storch (62yo)
Independent Director
- Tenure: 7.8yrs
- Compensation: US$325.00k
Alan Lacy (65yo)
Independent Director
- Tenure: 11.8yrs
- Compensation: US$340.81k
Vicki Sato (70yo)
Lead Independent Director
- Tenure: 2.4yrs
- Compensation: US$388.31k
Mike Grobstein (76yo)
Independent Director
- Tenure: 12.6yrs
- Compensation: US$355.00k
Dinesh Paliwal (62yo)
Independent Director
- Tenure: 6.3yrs
- Compensation: US$307.50k
Matt Emmens (67yo)
Independent Director
- Tenure: 2.7yrs
- Compensation: US$345.00k
Bob Bertolini (58yo)
Independent Director
- Tenure: 2.7yrs
- Compensation: US$324.16k
Pete Arduini (54yo)
Independent Director
- Tenure: 3.5yrs
- Compensation: US$332.75k
Giovanni Caforio (54yo)
Chairman of the Board & CEO
- Tenure: 4.4yrs
- Compensation: US$19.38m
Karen Vousden (61yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$321.10k
Company Information
Bristol-Myers Squibb Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bristol-Myers Squibb Company
- Ticker: BMY
- Exchange: NYSE
- Founded: 1887
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$87.023b
- Shares outstanding: 1.64b
- Website: https://www.bms.com
Number of Employees
Location
- Bristol-Myers Squibb Company
- 430 East 29th Street
- 14th Floor
- New York
- New York
- 10016
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BMY | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Jan 1968 |
| BMY * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1968 |
| BRM | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BRM | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1968 |
| BMY | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1968 |
| 0R1F | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1968 |
| BMYS | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1968 |
| BMY | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH REP 1 COM USD0.10 | AR | ARS | Mar 2009 | |
| BMYB34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EA REPR 1 COM SHS | BR | BRL | Aug 2012 |
Biography
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiova ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 23:33 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.